Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.85
+0.41004.86%
Post-market: 8.850.00000.00%19:24 EDT
Volume:4.79M
Turnover:41.72M
Market Cap:1.85B
PE:-20.58
High:8.93
Open:8.36
Low:8.28
Close:8.44
Loading ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

Simply Wall St.
·
26 Nov 2024

BioCryst launches Orladeyo in ireland

TIPRANKS
·
18 Nov 2024

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator

MT Newswires Live
·
18 Nov 2024

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

GlobeNewswire
·
18 Nov 2024

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire
·
06 Nov 2024

BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
05 Nov 2024

BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays

Dow Jones
·
05 Nov 2024

Evercore ISI Reaffirms Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
05 Nov 2024

BioCryst Announces Strong Q3 2024 Revenue Growth

TipRanks
·
05 Nov 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Nov 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Nov 2024

BioCryst Pharmaceuticals, Inc. : Barclays Raises Target Price to $8 From $7

THOMSON REUTERS
·
05 Nov 2024

BioCryst price target raised to $8 from $7 at Barclays

TIPRANKS
·
05 Nov 2024

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
05 Nov 2024

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

GuruFocus.com
·
05 Nov 2024

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

Motley Fool Transcribing
·
05 Nov 2024

BioCryst Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
04 Nov 2024

Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss

Stock Track
·
04 Nov 2024

BRIEF-BioCryst Reports Q3 2024 Financial Results And Provides Business Update

Reuters
·
04 Nov 2024

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
04 Nov 2024